Quantcast
Channel: Italy Headlines on One News Page [United States]
Viewing all 40166 articles
Browse latest View live

From Italy to Trump, why are investors so complacent about political risk?

0
0
As Theresa May plotted with her Cabinet this weekend about the country’s plan for Brexit, doomsday-predictors should have every reason to be amazed at where asset prices sit today.

Funnily enough, market-savvy Brexiteers I spoke to in the aftermath of the vote were surprised but sanguine, saying markets always overreact. Clearly in the short term they were right, with the reaction to Brexit unexpectedly benign. But I do think it’s worth asking whether investors have become too complacent about political uncertainty as a result. Here we are two months on and investors seem more relaxed about political risk than they were pre-vote.

*Italian referendum*

Last month I spoke to Italian Prime Minister Matteo Renzi about the country’s constitutional reform referendum later this year. He has suggested in the past that, if he loses this vote, he will resign and nothing he said to me recently convinced me otherwise. Italy has had 63 governments in 70 years so greater stability is desperately needed, yet voters are pretty evenly split according to the polls.

*Read more*: Head to Italy for this summer’s Eurozone crisis

Why aren’t investors more concerned? Especially when you consider that Italian banks faced huge selling pressure after the Brexit vote amid fears of a need for a larger scale bailout. These things haven’t gone away and the last thing the country needs is political upheaval at this moment.

*US presidential election*

Italy isn’t the only consideration in the fourth quarter. According to the polls, Donald Trump winning is just as unlikely as a Brexit win was two months ahead of the referendum. Didn’t Brexit teach us not to count our chickens? Yet investors seem totally nonplussed.

Perhaps Trump has scared people enough that he’s thrown his chances away. Perhaps it is the fact that we don’t know what kind of President Trump would make. We can definitely question whether he will really be at daggers drawn with China, whether the Mexican Wall will really be built, and whether Nato really is so unimportant in his eyes. We just don’t know.

*Read more*: The latest Clinton email twist lays bare America's miserable choice

On the plus side, either presidential choice will likely bring further fiscal spending and that’s a reason for markets to rejoice.

*Monetary and fiscal policy*

It would be foolish to assume that the buoyancy in markets is purely fuelled by complacency, particularly when the rally feels so unloved. In fact, the real data so far in the UK seems to suggest that the fears of a collapse in the economy predicted by the surveys were greatly exaggerated – for now at least. The same is true in Europe. And where central banks are concerned, the belief is that lower for longer rates could very easily be lower for just about forever.

Political risk was also washed away by the continued waves of monetary stimulus. There’s more and more talk of fiscal spending support around the world not only from US electoral candidates but also from the UK government, Japan and in Europe.

The only central bank that could reverse the mood this year is the Fed. Janet Yellen acknowledged the improvement in the US economy at Jackson Hole last week and that message was strengthened by vice chair Stanley Fischer. Yet most analysts and investors believe that an interest rate hike will come in December or later. Another reason to hold your nose and buy.

*Still reasons to be cautious*

So the monetary environment still feels supportive for risk sentiment. I get that. Then add in investors’ apparent ability to shrug off impending doomsday scenarios similar to the Brexit vote and you’ve got a solid recipe for a continued asset price rally.

But at these lofty heights in equity markets and with unknowns like Italy and the US presidential election ahead of us, I’d argue there’s still reasons to be cautious. Reported by City A.M. 4 hours ago.

6,500 refugees rescued off Libya coast: Italian coastguard

0
0
6,500 refugees rescued off Libya coast: Italian coastguard --> Tue, 30 Aug 2016-09:13am , Rome , PTI According to the UN refugee agency, the total number of arrivals in Italy in 2016 was at around 105,000 The Italian coastguard said it had coordinated the rescue of about 6,500 refugees off of... Reported by WorldNews 3 hours ago.

Ventura: I´ll probably manage Chelsea when Conte leaves

0
0
Giampiero Ventura joked that he will manage Chelsea when Antonio Conte eventually departs as the new Italy boss attempts to […] Reported by SoccerNews.com 2 hours ago.

Around 6,500 migrants saved off Libyan coast

0
0
Italian naval ships and vessels from aid organizations on Monday rescued up to 6,500 Europe-bound migrants off the coast of Libya, according to Italy’s coastguard. Reported by France 24 2 hours ago.

Catholic and Shia Muslim leaders unite to condemn WMDs, terrorism

0
0
Rome, Italy, Aug 30, 2016 / 12:02 am (CNA/EWTN News).- Shia Muslim religious leaders from Iran and U.S. Catholic bishops say they have a common fight against weapons of mass destruction, terrorism, and violent religious extremism.

“Christianity and Islam share a commitment to love and respect for the life, dignity, and welfare of all members of the human community,” they said in an Aug. 18 joint declaration. “Peaceful coexistence is built on equity and justice. We call upon all to work toward developing a culture of encounter, tolerance, dialogue, and peace that respects the religious traditions of others.”

The two delegations agreed that belief in one God unifies Jews, Christians, and Muslims.

“Religious leaders must provide moral guidance and speak out against injustice and anything that is harmful to humankind,” said the declaration, titled “Gathered in the name of God.”

Cardinal Theodore McCarrick, Archbishop Emeritus of Washington, signed the document, as did Bishop Oscar Cantú of Las Cruces, who chairs the U.S. bishops’ Committee on International Justice and Peace.

The joint declaration followed a June 5-10 meeting in Rome. The dialogue built upon a meeting in Qom, in northern Iran, in March 2014 which focused on the elimination of nuclear weapons.

Bishop Cantú said the joint declaration is the fruit of “sincere dialogue between two religions that are united in their concern for the life and dignity of the human person.”

“Together, we commit ourselves to continued dialogue on the most pressing issues facing the human family, such as poverty, injustice, intolerance, terrorism, and war,” he added, according to the U.S. bishops’ conference.

The Iranians who signed the document are Ayatollah Ali-Reza A'arafi, president of Al-Mustafa International University, and Dr. Abdul-Majid Hakim-Elahi, director of the International Affairs Office of the Society of Qom Seminary Scholars.

The joint declaration rejected the development and use of weapons of mass destruction as well as “all acts of terrorism.”
 
“Together we are working for a world without weapons of mass destruction. We call on all nations to reject acquiring such weapons and call on those who possess them to rid themselves of these indiscriminate weapons, including chemical, biological, and nuclear weapons,” the declaration said.

The religious leaders similarly opposed “indiscriminate sanctions” and other policies that harm innocent civilians, like the forced expulsion of people from their homelands.

They also rejected extremism.

“We remain gravely concerned by the spread of extremist ideologies, often fueled by superficial and erroneous readings of religious texts, that negate the inherent worth and dignity of every person, regardless of religious belief,” their declaration said. “We call upon religious and community leaders to confront the spread of such ideologies that induce sectarianism and violence.”

They characterized violent extremism and terrorism as “perversions of authentic religious belief.”

“The guilt of terrorist acts should not be assigned to members of an entire religion, nationality, culture, race, or ethnic group,” they added. “Countering violent extremism requires firm determination and cooperation to address its root causes.”

“We call upon all to work toward developing a culture of encounter, tolerance, dialogue, and peace that respects the religious traditions of others,” they said.

“Serving God requires working for the welfare of all His creatures and the common good of humanity. Religious leaders must provide moral guidance and speak out against injustice and anything that is harmful to humankind,” said the declaration.

Other bishops in the Catholic delegation included Bishop Richard Pates of Des Moines nd Auxiliary Bishop Denis Madden of Baltimore. The five-member Iranian delegation was headed by Ayatollah Mahdi Hadavi Moghaddam Tehrani and Ayatollah Abolghasem Alidoost. Reported by CNA 2 hours ago.

Verratti not happy at PSG – Ventura

0
0
Paris Saint-Germain midfielder Marco Verratti is not happy at the French champions, according to Italy coach Giampiero Ventura. As Ventura […] Reported by SoccerNews.com 32 minutes ago.

Ventura: I'll probably manage Chelsea when Conte leaves

0
0
Ventura: I'll probably manage Chelsea when Conte leaves Having succeeded the Blues boss at both Bari and now the Italy national team, the 68-year-old has joked that he is a natural successor to his compatriot at Stamford Bridge Reported by Goal.com 38 minutes ago.

Verratti not happy at PSG - Ventura

0
0
Verratti not happy at PSG - Ventura The Italy boss claims the midfielder is disheartened by the fact that he is currently playing in the number 10 role when he wants to operate as a playmaker instead Reported by Goal.com 15 minutes ago.

Italy rescues 6,500 migrants from Mediterranean

0
0
ROME (Reuters) - Some 6,500 migrants were saved off the Libyan coast in 40 separate rescue missions on Monday, the Italian coast guard said on Twitter, in one of the largest influxes of refugees in a single day so far this year. Reported by Reuters India 5 minutes ago.

WATCH: Israel scores a wonder lob goal over Italy's Gianluigi Buffon

0
0
Not many players get to score a goal this pretty in their career Reported by CBS Sports 12 hours ago.

Verratti proved himself in Italy win - Ventura

0
0
Verratti proved himself in Italy win - Ventura The Paris Saint-Germain midfielder set up Graziano Pelle for the Azzurri's opener, and his coach was delighted to see him make more impact in the final third Reported by Goal.com 11 hours ago.

Ventura: Verratti proved himself in Italy win

0
0
Ventura: Verratti proved himself in Italy win Giampiero Ventura was delighted with Marco Verratti's performance after the midfielder starred in a 3-1 win for Italy in Israel on Monday. Reported by Goal.com 11 hours ago.

Spain hit eight, Italy, Wales star, Kosovo begin well

0
0
Spain hit eight, Italy, Wales star, Kosovo begin well Spain scored seven second-half goals against Liechtenstein as they, Italy, Wales and Austria started their campaigns with wins while Kosovo drew their debut match in Finland. Reported by UEFA 11 hours ago.

Spain hit eight, Italy and Wales star, Kosovo begin well

0
0
Spain scored seven second-half goals against Liechtenstein as they, Italy, Wales and Austria started their campaigns with wins while Kosovo drew their debut match in Finland. Reported by UEFA 11 hours ago.

'I owe him so much' - Immobile praises new Italy boss Ventura

0
0
'I owe him so much' - Immobile praises new Italy boss Ventura The 26-year-old hailed the impact of the Azzurri coach after scoring the decisive goal in a 3-1 win in Israel on Monday Reported by Goal.com 10 hours ago.

Death toll from Italy quake rises to 295

0
0
Rescuers have found the body of the last person reported missing after the deadly Aug. 24 earthquake in Italy, according to local media. Reported by euronews 4 hours ago.

Pope Francis meets hero dog who rescued girl in Italy earthquake aftermath

0
0
Pope Francis meets hero dog who rescued girl in Italy earthquake aftermath Pope Francis met Leo the black Labrador at the Vatican, along with his police handlers. The rescue dog saved four-year-old Giorgia in the town of Pescara del Tronto, central Italy. Reported by MailOnline 4 hours ago.

Afghan asylum seeker's body removed from Italy quake rubble

0
0
ROME (Reuters) - The body of an Afghan asylum seeker living in Amatrice, the town worst hit by last month's earthquake, was pulled from the rubble of the home where he had been living, Italy's national fire rescue service said on Monday. Reported by Reuters India 5 hours ago.

Indian men win against Cuba in Chess Olympiad

0
0
Indian men win against Cuba in Chess Olympiad *Chennai:* The Indian team in the open section continued its winning run defeating Cuba 2.5-1.5 in the fourth round of the World Chess Olympiad held at Baku, Azerbaijan on Monday.

While Indian Grandmaster (GM) and Chess Olympiad debutant Vidit Santosh Gujarathi won against his Cuban opponent, his team mates GM P. Harikrishna, B. Adhiban and S.P. Sethuraman split points with their opponents.

On the other hand, the Indian women's team drew its outing against Israel 2-2. World No.5 GM Harika Dronavalli and WGM Soumya Swaminathan drew their games against her Israeli opponent on the top and bottom boards respectively. The in-form International Master (IM) Tania Sachdev continued her winning streak defeating IM Kilinova.

http://images.mid-day.com/images/2016/jan/15khattar-s.jpg

*Gurgaon:* Haryana Chief Minister Manohar Lal Khattar handed over a cheque of Rs 3 lakh to the mother of national level swimmer Master Sagar Rana, who was injured in a swimming competition recently, to meet the expenditure made on his treatment.

http://images.mid-day.com/images/2016/jan/21Venus-s.jpg

*New York:* The sixth-seeded Venus Williams lost 4-6, 6-4, 7-6 (3) to 10th-seeded Karolina Pliskova of the Czech Republic in the fourth round of the US Open here on Monday.

"I was prepared that I'm going to play Venus. It's going to be tough, because all the people are cheering for her," Xinhua news agency quoted Pliskova as saying. Pliskova, 24, who reached last eight in major for first time in her career as she had never been past the third round in 17 appearances at majors before.

http://images.mid-day.com/images/2016/sep/1Andy-Murray-s.jpg

*New York:* Britain's Andy Murray was through to the quarter-finals of the US Open at Flushing Meadows here.

The second seed took out Grigor Dimitrov of Bulgaria 6-1, 6-2, 6-2 on Monday, Xinhua news agency reported.

http://images.mid-day.com/images/2016/aug/16Sania-Mirza-s.jpg*Sania Mirza* 

Bopanna and Gabriela enjoyed a strong start before going down 6-1, 2-6, 8-10 to Robert Farah of Columbia and Germany's Anna-Lena Groenefeld in 58 minutes here on Monday. Farah and Groenefeld will now take on the winners of the last eight clash between the seventh seeded American duo of Coco Vandeweghe and Rajeev Ram and the Czech-Crotian combination of Barbora Krejcikova and Marin Draganja.

Seventh seeds Sania Mirza and her Czech partner Barbora Krejcikova defeated unseeded American-Japanese pair of Nicole Gibbs and Nao Hibino 6-4,7-5 in a third round match. They won the match in an hour and 17 minutes, winning 31 winners, 12 more than their opponents and claiming 71 of the total 128 points played.

In the opening set of Bopanna's match, the first three games went with the serve until Bopanna-Gabriela clinched a service break to take a 3-1 lead. They then held their serve before forcing consecutive service breaks to win the first set.

Farah and Groenefeld staged a strong comeback in the second set, breaking their opponents in the fourth game to take the upper hand. They earned another service break in the eigth game to win the second set and draw level. In the tie-breaker, the Indo-Canadian combination started strongly, taking a 4-0 lead before Farah and Groenefeld won four consecutive points to draw level.

http://images.mid-day.com/images/2016/aug/8Zlatan-Ibrahimovic-s.jpg

The 34-year-old, who had played under Mourinho with Italian giants Inter Milan, had earlier rejected offers from Arsenal and Manchester City. But he decided to join Manchester United earlier this year after leaving French champions Paris Saint-Germain.

"I was close two times to moving to the Premier League -- once with Arsenal and then Manchester City. But it never happened and I don't need to play in the Premier League," Ibrahimovic was quoted as saying by Manchester Evening News on Sunday.

The star striker asserted that he had learned a lot from Mourinho during his stint at Inter Milan and informed that the Portuguese manager convinced him to move to Old Trafford.

"He is the mastermind, the masterbrain. He knows what he needs to do to win," Ibrahimovic said.

"I learned a lot from him at Inter. Who wouldn't want to have Mourinho as manager?"

Ibrahimovic, who has scored four goals in his first four games for Manchester United, is also reportedly planning to venture into football management when his playing days are over.

He will reportedly start his coaching course early next year in preparation for becoming a manager when he retires.

Ibrahimovic has also held talks with Mourinho about his plans once he hangs up his boots.*Manchester United manager Jose Mourinho believes veteran Zlatan Ibrahimovic's vast experience will help to inspire the club's young players. File Pic*

"Zlatan is already tapping into Jose Mourinho and planning for the future in the game. He has told the lads he does not see an end to his playing days for another two or three years," a Manchester United source was quoted as saying by the Sun.

"Jose has left his door open and Ibra likes the idea of coaching, but not necessarily a manager right away. He is enjoying picking up a few ideas and he fancies Italy."

Ibrahimovic, who started his career with Malmo FF in Sweden, represented top European clubs such as Juventus, Inter Milan, FC Barcelona and AC Milan before joining Paris Saint-Germain in 2012.

http://images.mid-day.com/images/2016/aug/Joe-Root-s.jpg

England batsman Joe Root has surged into the top five of the ICC Players Rankings for ODI batsmen for the first time after a stellar performance against Pakistan, which earned him the player of the series award.

The 25-year-old scored 274 runs in the series, which helped him leapfrog New Zealand’s duo of Kane Williamson and Martin Guptill as well as India batsman Rohit Sharma into fourth position in the latest player rankings.

During the series, the Yorkshireman also achieved a career-best rating of 776 points, which he had attained after the third ODI at Trent Bridge in which he scored 85.

Root in one of the four England batsmen to make upward movement following a 4-1 series win over Pakistan.

Alex Hales has risen four places to reach 20th spot after aggregating 223 runs in the series, including a belligerent 171 in the third ODI, captain Eoin Morgan has gained four places and is now in 24th spot, while Jason Roy’s series contribution of 181 runs have helped him rise 10 places to share 35th spot with Dinesh Chandimal, who himself has moved up 15 places following a good series with the bat against Australia.

The good news for Pakistan was the movement of its captain Azhar Ali and wicketkeeper Sarfraz Ahmed.

Azhar’s 208 runs in the series has seen him move up 15 places to 33rd rank, while Sarfraz, who was the highest run-getter in the series from either side with 300 runs, has moved up 21 places to 39th position.

Sarfraz had a productive series with the bat when he scored 55, 105, 38, 12 and 90 in the series.

Azhar and Sarfraz are the only two Pakistan batsmen, who featured in the recent series against England, to figure inside the top 50. The next highest Pakistan batsman is Shoaib Malik in 67th spot.

Australia, which scripted a similar 4-1 series win over Sri Lanka, saw Aaron Finch and George Bailey move up two and three places, respectively. Finch is now in 15th position while Bailey claims 17th spot.

Bailey finished the series as the most successful batsman with 270 runs, which later earned him the player of the series award, 34 runs more than Chandimal who ended up in 35th spot after rising 15 places.

AB de Villiers of South Africa is the number-one ranked ODI batsman, and he is followed by India’s Virat Kohli and team-mate Hashim Amla, in second and third positions, respectively.

In the MRF Tyres ICC Players Rankings for ODI Bowlers, Australia fast bowlers Mitchell Starc, James Faulkner and John Hastings have made significant gains after their performances in Sri Lanka.

Starc’s 12 wickets in the series have seen him move up from fifth to third place, Faulkner’s 10 wickets have helped him gain 15 places to reach 18th position, while Hastings has vaulted 22 places to achieve a career-best 24th rank following nine wickets in three matches.

In the series between England and Pakistan, the home side’s Adil Rashid has broken into the top 10 for the first time, while fast bowler Chris Woakes has carried his Test form into limited overs cricket by entering the top 20 for the first time.

Rashid has been rewarded for his eight wickets in the series with a rise of six places that has put him in 10th position, while Woakes has climbed 13 places to 16th after finishing as the leading wicket-taker in the series with nine wickets.

The bowlers’ table is led by Sunil Narine of the West Indies, while Trent Boult of New Zealand is in second place.

http://images.mid-day.com/images/2016/sep/5PV-Sindhu-s.jpg*PV Sindhu celebrates on the podium after receiving the silver medal at the Rio Olympics recently. Pic/Getty Images *

For starters, one hopes that Sindhu continues her great run and plays with confidence and consistency, which apart from the Olympics, we saw just once before when she gatecrashed to the finals of the Denmark open Super Series in 2015, blowing away on world beaters like Tai Tzu-ying of Chinese Taipei, Wang Yihan of China (Sindhu incidentally defeated both of these shuttlers at Rio also), and the then reigning world champion Carolina Marin of Spain. Sindhu lost to Li Xuerui. The tall Indian star had of course made a name for herself when she had defeated Xuerui, fresh from her London Olympics victory, at the 2012 China masters.

Barring Wang Shixian, another formidable Chinese, Sindhu has defeated all other current top stars. She has not played Saina Nehwal in any National or BWF event so far and it will be interesting to see both battling out after Saina Nehwal is back in action.

Can Sindhu be consistent?
Sindhu has enough events to consolidate her position in world rankings with six super series left in the year starting with Japan and Korean opens in September and ending with the China and Hong Kong opens in November. One hopes consistent performances will get her an entry among the top eight ranked players in the super series finals at Dubai, where the biggest ever purse of one million USD awaits the top players.

With Saina out of action for three months, Sindhu may well be the only Indian to qualify for Dubai. Barring these two queens of Indian badminton, hardly any other Indian shuttler can be termed as a world beater. The bench strength is just not there and the scene is not encouraging at all.

Let us see where our other players stand in world ranks to give an indication where Indian badminton stands today. After Saina at fifth spot (at the time of writing) and Sindhu at 10th, our next ranker is Tanvi Lad at 79, followed by Ruthvika Shivan in 84th place. In the women's doubles category, after Jwala Gutta/Ashwini Ponnappa at 22, the next duo of Maneesha/Sikki Reddy are 86th.

*Men's scene equally bad*
The men's doubles has Rio returnees Manu Attri/Sumeeth Reddy at 21 followed by Jerry Chopra/Akshay Dewalkar at 29. The next pairs are at the 61st and 82nd spots. In men's singles we have five players in the top 50, led by Kidambi Srikanth at 11, but none of our players are showing the required consistency that will propel Indian badminton to superpower status.

Saina remains our most consistent performer on the world stage till date. The Badminton Association of India (BAI) and the National coach must devise strategies to ensure that we have enough and strong bench strength in all events as early as possible.

We have the finance, talent and infrastructure but a middle to long term plan is urgently needed if India is to step into the shoes of badminton superpowers like China, Korea, Japan, Denmark etc. By 2018, the Thomas/Uber cups, the CWG and Asian games will be held, and Indian badminton should not be left wanting. The thrust given by PV Sindhu at Rio must be exploited to the hilt.

http://images.mid-day.com/images/2016/jun/14-dhoni-s.jpg

*New Delhi: *The Supreme Court on Monday quashed criminal proceedings against cricketer M S Dhoni for allegedly hurting religious sentiments by portraying himself as God on a magazine cover.

A bench headed by Justice Ranjan Gogoi granted the relief to Dhoni after noting that the trial court in Karnataka erred in summoning the cricketer without following the due procedure of law.

"We interfere with the order of the High Court and quash the proceedings including the summoning order against the accused... we have taken note of the complaint and the offence alleged while passing this order" the bench said.

On September 14, last year, the apex court had stayed the criminal proceedings against Dhoni on a complaint lodged for allegedly portraying himself as Lord Vishnu on a magazine cover page.

The court had also stayed the operation of the order of Karnataka High Court which had refused to stall the criminal proceedings against him. 

Dhoni had filed the Special Leave Petition challenging the Karnataka HC order.

The complaint, filed by social activist Jayakumar Hiremath, had alleged that Dhoni was seen on the cover of a business magazine as Lord Vishnu, holding several things, including a shoe in his hands.

Taking cognisance of the complaint, the Additional Chief Metropolitan Magistrate (ACMM) had directed registration of a case against Dhoni under section 295 (injuring or defiling place of worship with intent to insult the religion of any class) along with 34 (common intention) of the IPC.

Later, the ACMM had issued summons to Dhoni to appear before the court, against which he moved the High Court.RELATED STORIES*Local court in Andhra recalls its NBW order against Dhoni*

*Andhra court warrant against Mahendra Singh Dhoni erroneous, says lawyer*

*Lord Vishnu cover controversy: Non-bailable warrant against MS Dhoni*

*Lord Vishnu controversy: Now, SC suspends MS Dhoni trial*

*Lord Vishnu controversy: SC stays criminal proceedings against MS Dhoni*

http://images.mid-day.com/images/2016/sep/2Azhar-Ali-s.jpg

*Dubai:* Pakistan's hopes of automatic World Cup qualification toughened as they plummeted to their lowest-ever rating of 86 after losing the five-match ODI series 1-4 against England.

Despite the four-wicket consolation win in the fifth and final one-dayer on Sunday, Pakistan are in serious danger of failing to qualify automatically for the World Cup 2019 as they are now eight points behind eighth-ranked West Indies.

Pakistan had started the series on 87 points and this is their lowest-ever points tally since the current rankings system was introduced in 2001.

With Pakistan's forthcoming ODI series being against the West Indies and Australia, it has left itself with a mountain to climb to keep alive its chances of qualifying automatically for the ICC Cricket World Cup 2019.

However, Australia and England have consolidated their positions on the MRF Tyres ICC ODI Team Rankings after completing identical 4-1 series victories over their respective oppositions in the series which ended on Sunday. 

Australia, who scored a five-wicket win over Sri Lanka in the final match in Pallekele, has moved from 123 points to 124 points, and in doing so, has opened up an 11-point advantage over New Zealand.

They will now aim to reclaim the ICC Champions Trophy title to add to its World Cup trophy, when it is staged next year in the United Kingdom. 

Sri Lanka has retained its sixth position but has dropped a point to finish on 101 points.

Sri Lanka's one-point drop will interest seventh-placed Bangladesh, which is now just three points behind its Asian rival and has two upcoming three-match ODI series each against Afghanistan and England coming up.

If Bangladesh wins all the three matches against Afghanistan, plus manages a series win against England, then it will achieve its highest-ever ranking of sixth. 

Meanwhile, England, which will attempt to win its maiden 50-over ICC title when it hosts next year's ICC Champions Trophy, has sent out a warning to the other sides after its impressive series win against Pakistan. 

The series result against Pakistan has seen England move from 106 points to 107 points in fifth position -- three behind India and South Africa, who are at 110 points each with India ranked ahead of South Africa on decimal points.

http://images.mid-day.com/images/2016/sep/sehwag-gayle-rohit5sept-s.jpg

Virender Sehwag took to Twitter to post a picture along with West Indies trailblazer Chris Gayle and India's stylish opening batsman Rohit Sharma. He captioned the picture saying: 4 test triple centuries and 4 odi double centuries in one pic. With Universe Boss @henrygayle & Mr.Talent @ImRo45



4 test triple centuries and 4 odi double centuries in one pic.
With Universe Boss @henrygayle & Mr.Talent @ImRo45 pic.twitter.com/t88JF1IujW

— Virender Sehwag (@virendersehwag) September 4, 2016


http://images.mid-day.com/images/2016/sep/5Sandeep-Patil-s.jpg*Sandeep Patil is all set to end his four-year term as chairman of India selectors on a good note*

The delighted Patil, probably in his last month of his four-year term, agreed that he could relate to an 'A' triumph after having coached at that level several years ago. "I can imagine how happy Rahul Dravid (the current India 'A' coach) must be. Anil Kumble is doing a fabulous job with the senior team, but the 'A' team is your bench strength. It's critical," Patil told mid-day yesterday.

Earlier in the day, the Indians beat the hosts by 57 runs after the spinners, led by leg-spinner Yuzvendra Chahal, combined to bowl out the Australians for 209 in pursuit of a 267-run target. "I will be a very happy man to finish on this good note. I am personally very happy with the way things have moved," Patil said.

*'There is always pressure'*
Beating Australia 'A' in their backyard would have provided more reason to celebrate, but Patil didn't read too much into that special satisfaction. "Whether it is Bangladesh, Australia, Sri Lanka… there is always pressure. It is international cricket, after all. You know that we struggled in Bangladesh too. We are happy the boys are using this platform well," said Patil, agreeing that the satisfaction of this win is more because it bodes well for the future.

Success of 'A' teams lessens the worry over replacing players who either get injured or suffer a loss of form and considering the 13-Test season is close at hand, Patil has no concerns. He remarked: "We are not worried about replacements. Anil has worked out a great plan where players will be going to the National Cricket Academy regularly. Looking at 13 Tests at home - especially the medium pacers - we have a replacement ready for each and every player. Not one, but three replacements.

"We had a long chat with Anil, Virat Kohli and MS Dhoni and we have given them options as to who can replace whom in the home series be it T20, ODIs and Test cricket."

*'Mandeep is brilliant'*
Reacting to yesterday's show in Mackay, Patil stressed: "Yes, I expected good things from Mandeep Singh (who scored 95 in the final). He is a brilliant talent, but again, he is not the only one. Shreyas Iyer too is very gifted. We have picked these young players looking at the road ahead.

http://images.mid-day.com/images/2016/sep/nadal5sept-s.jpg*Rafael Nadal of Spain reacts against Lucas Pouille of France during his fourth round Men's Singles match on Day Seven of the 2016 US Open. Pic/ AFP*

The Spanish tennis star and 14-time Grand Slam winner thus, failed to reach the quarterfinals. The 22-year old Pouille, who is ranked 25th in the world came out triumphant in what was a gruelling encounter.

Rafael Nadal in the process, has now not made a quarterfinal appearance in a Grand Slam for the first time since 2004.

http://images.mid-day.com/images/2016/sep/5Sania-s.jpghttp://images.mid-day.com/images/2016/sep/5Courtney-Walsh-s.jpg*Bangladesh's newly appointed bowling coach Courtney Walsh speaks to the media in Dhaka yesterday. Pic/AFP *

"I have always dreamed of being involved with an international team," Walsh said in his first press conference in Dhaka yesterday. "There was a natural instinct to come here. I have never ever played in Bangladesh in my career. I played against them a couple of times.

"It was another chance to make new friends, and I always like challenges and get a satisfactory end result at the end of everything. It is a combination of both. I am happy to be here," he said. Walsh, who took 519 Test wickets and 227 in ODIs in a 17-year international career, replaced former Zimbabwean captain Heath Streak in the position.

http://images.mid-day.com/images/2016/sep/5Mayank-Agarwal-s.jpg*Mayank Agarwal*

In 33 innings of his 20 first class games before this one, he had one century and eight half-centuries. The previous game against India Red, Agarwal was stumped on 92. His reputation as someone having regular brain fades after getting set was creating indifferent opinions in the cricketing circles. His inconsistency had cost him to be benched in most of the games in the 2014-15 season for Karnataka. In a post-match press conference during the last game, the 25-year-old would say that he would look "at the brighter side, though it is quite hurtful to have missed out (on a century)."

Batting with Gambhir, Agarwal in the last game termed it a "tremendous experience" and learning points like "when the ball is moving; not to follow the ball and just play the line."

http://images.mid-day.com/images/2016/sep/5Sakshi-Malik-s.jpg*Sakshi Malik during the Rio medal ceremony. Pic/Getty Images*

Announcing this, Haryana Sports and Youth Affairs Minister Anil Vij also said that she will be given Rs 21 lakh out of his discretionary fund and a plot measuring 500 square yards. Her coach Mandeep would be given promotion under special rules, Vij said yesterday.

The Haryana government has, in recognition of her achievement, already felicitated Sakshi Malik, who hails from Rohtak district, with a cash reward of Rs 2.5 Cr under its Sports Policy.

The sports minister was speaking at a function at Rohtak late evening where hockey players—Savita Punia and Poonam Rani and wrestler Virender Singh were also
felicitated.

Vij said that during his visit to Rio Olympics, he met players, coaches and other people of various countries.

http://images.mid-day.com/images/2016/sep/5Sindhu-Dipa-Sakshi-s.jpg*PV Sindhu, Dipa Karmaka and Sakshi Malik*

"We are very keen to involve both Olympic medal winners Sakshi Malik and P V Sindhu along with gymnast Dipa Karmakar, in Swachh Bharat Mission. The stories about role of hygeine and sanitation in their sucess will be great booster for this mission," Secretary, Drinking Water and Sanitation, Parameswaran Iyer told PTI.

He said these sportstars can inspire many women, especially in rural areas. "We will apporach Sports Ministry for involving these olympians," he said.

Modi had nominated 27 prominent personalities from various walks of life for promoting his pet programme.

The list includes Amitabh Bachchan, Ramdev, Sachin Tendulkar and Anil Ambani, among others.

For achieving universal sanitation and to put focus on hygiene, Modi launched the Swachh Bharat Mission on October 2, 2014.

The Mission is coordinated by the Secretary of Drinking Water and Sanitation (MDWS) with two Sub-Missions, the Swachh Bharat Mission (Gramin) and the Swachh Bharat Mission (Urban), which aims to achieve universal sanitation (Swachh Bharat) by 2019.

http://images.mid-day.com/images/2016/sep/5India-s.jpg*India 'A' players celebrate with the Quadrangular winner's trophy after their 57-run win over Australia 'A' in Mackay yesterday. Pics/Getty Images*

A well composed 95 from opener Mandeep Singh and Manish Pandey's 61 propelled India to 266 for four in the alloted 50 overs before Yuzvendra Chahal spun a web around the Aussie middle order to end with impressive figures of 4-34. The hosts were bowled out for 209 in 44.5 overs.

Mumbai pacer Dhawal Kulkarni (2-22), Karun Nair (2-29) and Axar Patel (2-33) chipped in.

Earlier, Mandeep shared a 81-run stand off 108 balls with Shreyas Iyer (41) for the second wicket before adding 87 for the third wicket with skipper Pandey.*India A's Mandeep Singh en route his 95 vs Australia 'A'*

Captain Peter Handscomb (43) was the top run-scorer for hosts while Cameron Bancroft and Alex Ross scored 34 each.

Man of the match, Mandeep revealed how India 'A' coach, Rahul Dravid relaxed the team ahead of the final by telling the players to be calm and not try 'too hard'.

Commenting on his match-winning innings, Mandeep said, "It is very satisfying to get a big score. I'm delighted how I constructed my innings. It is a big ground and to build a score here you need to run plenty of twos and threes. I felt I did that really well today. Normally in India, the boundaries are short so we are not used to playing in this manner all the time."*Leggie Yuzvendra Chahal (right) celebrates the wicket of Australian Kane Richardson with wicketkeeper Sanju Samson yesterday*

While the celebrations were not over the top, a member of the support staff told mid-day that Dravid was extremely impressed by the way the team had gelled as the tournament progressed.

"The part that impressed the coach was the fact that each single player contributed at various stages in the tournament. Like today, Karun Nair only managed one run but picked up two crucial wickets. After an unhappy tour leading up to the final, Mandeep Singh stood out in the final."

Dravid was also thrilled by the way the team had rebounded after being skittled for mere a 55 in their opening match.

Yesterday, he asked his players to soak in the win and continue their form in the four-day matches starting in Brisbane on Thursday.Scorecard*India 'A'*
M Singh c Bancroft b Mennie 95
K Nair b Worrall 1
S Iyer c Bancroft b Stoinis 41
M Pandey c Worrall b Tremain 61
K Jadhav not out 25
A Patel not out 22
Extras (b 1, lb 5, w 15) 21 Total (4 wickets; 50 overs) 266 Fall of wickets 1-2, 2-83, 3-170, 4-239
Bowling
C Tremain 10-1-42-1
D Worrall 9-0-52-1
K Richardson 10-0-55-0
J Mennie 8-1-37-1
C Boyce 8-0-44-0
M Stoinis 5-0-30-1

*Australia 'A'*
C Bancroft b Nair 34
K Patterson b Kulkarni 19
N Maddinson c Samson b Nair 31
P Handscomb c Iyer b Patel 43
A Ross c Samson b Kulkarni 34
M Stoinis c Iyer b Chahal 12
K Richardson c & b Chahal 2
J Mennie c Jadhav b Patel 5
C Tremain c Jadhav b Chahal 2
C Boyce c Iyer b Chahal 6
D Worrall not out 3
Extras (b 4, lb 7, w 7) 18 Total (all out; 44.5 overs) 209 Fall of wickets 1-31, 2-82, 3-91, 4-168, 5-183, 6-189, 7-189, 8-199, 9-200
Bowling
D Kulkarni 7-0-22-2
J Unadkat 7-0-37-0
H Pandya 8-0-43-0
Y Chahal 8.5-0-34-4
K Nair 6-0-29-2
A Patel 8-1-33-2

http://images.mid-day.com/images/2016/sep/5Serena-Williams-s.jpg*USA's Serena Williams serves against Sweden's Johanna Larsson during her Round Three match in New York on Saturday. Pic/Getty Images*

Williams dominated Sweden's Johanna Larsson 6-2, 6-1. Not only has she surpassed Navratilova for most Grand Slam wins by a woman, she equalled Roger Federer's mark for men. "I was really excited to reach 307," Williams said.

"It's something I didn't even know about until Wimbledon — it was like a new goal. That was pretty cool for me. "Obviously I want to keep that number going higher," added Williams. "And what better place to do it than here where it all started," said Williams, who claimed the first of her 22 Grand Slam singles titles at the 1999 US Open.

A 23rd major triumph would take her past the Open Era record she now shares with Steffi Graf and closer to Margaret Court's all-time record of 24.

But the US superstar has been slowed by a right shoulder injury since her Wimbledon triumph. "It definitely feels solid," she said of the shoulder, which didn't appear to trouble her in the one hour she needed to subdue Larsson.

http://images.mid-day.com/images/2016/sep/5HS-Prannoy-s.jpg*HS Prannoy*

Prannoy alongwith Sai Praneeth, PC Thulasi, Siril Verma and Ruthvika Shivani had booked a flight MH 0199 from Hyderabad to Kuala Lumpur in the early hours yesterday but it got delayed, which meant they missed the connecting flights from Malaysia to Jakarta and Balikpapan.

"Malaysia airlines completed messed it up. Our Hyderabad to Malaysia flight got delayed. So we missed the connection from Malaysia to Jakarta. They gave next flight from Malaysia then but that was also delayed by 3 hours. So we missed our Jakarata-Balikpapan flight as well, " Prannoy told PTI.

"So now we had to buy one ticket for Rs 10000 for the night flight. There is no refund from Malaysia Airline. We are not waiting at Jakarta airport. And now even the night flight again got delayed by 2 hours. So I hope I reach there today morning, " a frustrated Prannoy added.

The tournament starts on September 6 but their matches will be held on September 7.

"At least we are lucky the matches are on September 7. If it was on September 6 then it would have been better to concede the match then go there," said Prannoy, who is supported by GOSPORTS foundation.

http://images.mid-day.com/images/2016/sep/5Wayne-Rooney-s.jpg*Wayne Rooney*

Team captain Rooney, 30, surpasses his former England team-mate David Beckham, who was capped 115 times by his country. Goalkeeper Peter Shilton, capped 125 times, holds the overall record. "I think it is always important and an honour to represent your country," Rooney said on the eve of the game in Trnava.

"To do it the second-most times will be great, but tomorrow (Sunday) is about the team, about getting three points. "I'm sure one day in the future I will look back, but for now I'm looking to the game tomorrow and nothing else."

Rooney is also England's record goal-scorer with 53 goals, having broken Bobby Charlton's longstanding record of 49 in September 2015.

http://images.mid-day.com/images/2016/sep/5Stephen-Constantine-s.jpg*Stephen Constantine*

"Sunil Chhetri is the talisman of this team. He is a wonderful player. He has been scoring goals for the last 10 years. I keep teasing him, saying 'your time is almost done', but he's not having that. He says he has another 4-5 years in him," said Constantine after India's key player set up two goals and scored one in a dazzling display of creative football at Andheri Sports Complex that hosted its first major game.

*Fitness matters*
"But look, he keeps himself in great shape. He is one of the leaders of the team, the captain. And as long as he's fit, he plays," said the Englishman after India, ranked 152 on the FIFA table, humbled Puerto Rico, ranked 114, by coming back from a goal down.

Constantine also said that Chhetri, the regular captain who gave away his armband for the game in favour of Norway-based goalie Gurpreet Singh Sandhu, can play in multiple positions up front.*India's Sunil Chhetri (left) tries to dribble the ball past Puerto Rico's Juan Velez during the friendly at Andheri Sports Complex in Mumbai on Saturday. Pic/AFP*

"A player of his calibre, you have to find the space for him. For me, his place is behind the striker. He brings other people into the game. He has an eye for goals, he sees the pass, and he works. It's not like he's walking about. Personally, I like to play him behind the striker," said the coach.

*No fixed slot for Chhetri*
"However, there is no lock on his position. In some games, I like him on the left or the right, but at this point in his career, I see him playing behind the striker," he added in praise of the country's highest goal-scorer.

http://images.mid-day.com/images/2016/sep/5Andy-Murray-s.jpg*Andy Murray*

Murray was far from his best in Arthur Ashe Stadium but he dug deep to win 7-6 (7/4), 5-7, 6-2, 6-3 and book a fourth-round meeting with Bulgaria's Grigor Dimitrov.

The Scot has still only dropped one set so far this year at Flushing Meadows but he made 63 unforced errors against Lorenzi — three times as many as he committed in either of his opening rounds.

After a poor second set, however, Murray tightened up in the third and fourth, pulling away from the Italian to seal a routine victory. "It took me a little bit longer than I would have liked to work things out but I won, got through, and I didn't play good so I'm happy with that," Murray said.

"He's ranked 40 in the world. He's pretty good, so I expected a tough match. I expected long rallies.

http://images.mid-day.com/images/2016/sep/5Abhinav-Bindra-s.jpg*Abhinav Bindra*

Bindra, India¿s lone individual Olympic gold medallist, today officially announced his retirement from shooting, saying,"It is time to move on and hand over the baton to the younger generation".

Bindra had earlier announced that Rio Olympics would be his last competitive event. After ruling the shooting range for more than a decade, Bindra, who will soon turn 34, hads set his sights on his new business venture.

"I am trying to earn a living. I am involved in business, trying to earn a living, put food on the plate. Well I am interested in sport but sport you know is not going to give me much money. I am involved in certain things, which is to do with fitness, doing something on the medical side, and I am also trying to do something on high performance side of sports," Bindra told reporters during an interaction on the sidelines of his farewell function.

"The role of sports science, sport medicine is incredibly important in modern day sport. We can't do without it. I don't think the whole concept is actually strong enough in our country," the 10-metre air rifle ace added.

At the end of his illustrious career, Bindra was asked about his vision for Indian sports. "I would like Indian sport to grow and I think that can be only possible if we are able to invest in grassroots and set up programmes and systems for people to come in and join sport. That requires investment, that requires expertise, it also requires a lot of patience, and it also requires will," Bindra said.

http://images.mid-day.com/images/2016/sep/5David-Warner-s.jpg*David Warner*

Australia, who had clinched the series in Dambulla on Wednesday, rode on a record 132-run partnership between Warner (106) and George Bailey (44) to chase down 196 in
43 overs on a sluggish pitch.

Earlier pace spearhead Mitchell Starc led the visiting attack with three wickets to bowl out Sri Lanka for a modest 195 in 40.2 overs.

http://images.mid-day.com/images/2016/sep/5Nick-Kyrgios-s.jpg*Nick Kyrgios gets treated for an injury on Saturday. Pic/AFP*

The 14th seed needed a medical timeout after dropping the second set and despite a series of further checks with the trainer, he quit after the third set feeling unable to move effectively enough around the Arthur Ashe Stadium court.

"It's tough. I don't like to retire. It's probably like the second or third time I've done it," said 21-year-old Kyrgios who was bidding to make the last 16 at Flushing Meadows for the first time.

http://images.mid-day.com/images/2016/sep/5Bernie-Ecclestone-s.jpg*Bernie Ecclestone*

The well-sourced German magazine Auto Motor und Sport said that Bernie Ecclestone had confirmed the deal. The magazine reported that Ecclestone said Liberty Media will make the first of two payments on Tuesday in a deal valued at 8.5 billion dollars.

http://images.mid-day.com/images/2016/sep/5Venus-Williams-s.jpg*Venus Williams. Pic/AFP*

http://images.mid-day.com/images/2016/sep/5Nico-Rosberg-s.jpg*Mercedes driver Nico Rosberg (top) celebrates his Italian Grand Prix victory with his crew at Monza in Italy yesterday. Pic/AFP*

Rosberg roared into the lead at the first corner when pole-sitter Hamilton became bogged down and pulled away to control the race with calm aplomb and finish 15 seconds clear of the defending three-time champion.

Sebastian Vettel came home third, 5.9 seconds further adrift, ahead of his Ferrari teammate Kimi Raikkonen.

It was Rosberg's first Italian win, his seventh of the season and 21st of his career, reviving his championship challenge with seven races remaining.

*Brilliant start for Nico*
"It was all down to the start. I had an awesome start and it was all from there," beamed Rosberg.

It was also the 50th podium finish of Rosberg's career and prevented Hamilton completing a cherished hat-trick of Italian wins, to equal a feat achieved only once before by Juan Manuel Fangio in the 1950s, and register his 50th career victory.

It was the first time in seven years that the race was not won by the driver starting from pole position. "Good job!" Hamilton grimaced as he shook hands with Rosberg afterwards.

*Battle ahead for Lewis*
Hamilton, who effectively lost the race in the first 20 metres when the lights went out, now leads the title race with 250 points ahead of Rosberg on 248 and knows, from the look on his face, that he has a battle to stay in front.

"Thank you everybody," said Rosberg.

http://images.mid-day.com/images/2016/sep/5Victoria-Beckham-s.jpg*Victoria Beckham. Pic/Getty Images*

Former footballer David's wife said she had just as many imperfections and insecurities as the next teen and she isn't afraid to look back at them now, reported Vogue magazine.

"I know you are struggling right now. You are not the prettiest, or the thinnest, or the best at dancing at the Laine Theatre Arts college. You have never properly fitted in, although you are sharing your Surrey school digs with really nice girls.

http://images.mid-day.com/images/2016/sep/5Kobe-Bryant-s.jpg*Kobe Bryant*

As a player, the five-time NBA champion joined other high-profile stars, including LeBron James, in expressing solidarity with victims of police violence against African Americans.

http://images.mid-day.com/images/2016/sep/5Sania-Leander-Rohan-s.jpg*Sania Mirza exults during her women's doubles match on Saturday. Pic/AP,PTI*

Sania and Barbora Strycova of Czech Republic advanced to the third round of the women's doubles after a 6-2, 7-6(5) win over Viktorija Golubic and Nicole Melichar.
The seventh seeded pair will now meet unseeded Nicole Gibbs and Nao Hibino next.

Bopanna and his Canadian partner Gabriela Dabrowski defeated Lukasz Kubot and Andrea Hlavackova 5-7, 6-3, 10-7 to move into the quarterfinals.*Leander Paes and Rohan Bopanna*

The pair will next meet unseeded pair of Robert Farah and Anna-Lena Grönefeld.

However, defending champions Paes and Hingis lost to American seventh seeds Coco Vandeweghe and Rajeev Ram 7-6 (1), 3-6, 13-11 after leading 8-4 in the match tiebreaker at Flushing Meadows.

http://images.mid-day.com/images/2016/sep/5Jason-Roy-s.jpg*England's Jason Roy (L) plays a shot as Pakistan's Sarfraz Ahmed keeps wicket during play in the fifth one day international (ODI) cricket match between England and Pakistan at The SWALEC Stadium in Cardiff, south Wales. Pic/AFP*

Roy made 87 and Stokes an ODI-best 75 as England, bidding for a first 5-0 clean sweep of a home one-day series, set Pakistan a challenging total to chase.

At 244 for five England — who posted a world record 444 for three in the third ODI in Nottingham — were set for another huge score. But Pakistan pegged them back with paceman Hasan Ali taking an ODI best four for 60 and left-arm quick Mohammad Amir three for 50.

Opening batsman Roy, dropped on 56 when a diving Mohammad Rizwan could not hold a tough chance at mid-wicket, put on 72 for the fourth wicket with Stokes. All-rounder Stokes and wicket-keeper Jonny Bairstow then added 55 for the fifth wicket.

England made a rapid start after being sent into bat on a green-tinged pitch and under overcast skies by Pakistan captain Azhar Ali. Reported by Mid-Day 4 hours ago.

Biocartis Group NV: Biocartis announces H1 2016 results

0
0
PRESS RELEASE: REGULATED INFORMATION

Tuesday, 6 September 2016, 07:00 CEST

BIOCARTIS ANNOUNCES H1 2016 RESULTS

*Mechelen, Belgium* , *6 September* *2016 -* Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces its operational highlights and financial results for the first half of 2016, prepared in accordance with the IAS 34 Interim Financial Reporting as adopted by the European Union. Furthermore, the Company provides an updated outlook for 2016.

*KEY MESSAGES*

· *General:* H1 2016 demonstrates an initial validation of Biocartis' razor-razorblade business model as the increased installed base of Idylla(TM) instruments and broadened menu of Idylla(TM) tests are resulting in an accelerated growth of cartridge consumption.
 
· *Cartridge volume:* Commercial cartridge volume in H1 2016 was more than twice the volume for the full year 2015 number.
 
· *Installed base:* A total of 106 Idylla(TM) instruments were added to the installed base in H1 2016, bringing the total to over 270 as per 30 June 2016. Guidance on instrument placements for 2016 is now set at the top end of the targeted 150 - 175 range.
 
· *Menu expansion:* Launch of the Idylla(TM) EGFR Mutation Assay, a key addition to Biocartis' core menu for oncology and first U.S. FDA achievement with the granting of the Emergency Use Authorisation (EUA) for the Idylla(TM) Ebola Virus Triage Test. Guidance to launch at least four new tests in 2016 reiterated.· *Financials:* Product revenues increased to EUR 2.7m in H1 2016 compared to EUR 1.7m in H1 2015, an increase of 63%. Total operating income over the same period decreased with 7% to EUR 6.8m (EUR 7.2m in H1 2015) as no new milestone payments were collected in H1 2016. Cash and cash equivalents on 30 June 2016 amounted to EUR 75.8m. Guidance on end of year cash position in the range of EUR 45m to EUR 55m reiterated.

The Biocartis management team will host a conference call with live webcast presentation today at 14:00 CEST / 13:00 BST (UK) / 08:00 EDT (US) to discuss the H1 2016 results. The live webcast may be accessed by clicking here .

To participate in the questions and answers session, please dial 5-10 minutes prior to the start time the number +44(0)20 3427 1908 (standard international), followed by the confirmation code 6014209.

The conference call and webcast will be conducted in English.
A replay of the webcast will be available on the Biocartis investors' website shortly after.

*Commercial highlights*
Biocartis commercialises its proprietary molecular diagnostics platform Idylla(TM) via direct representations in key European countries and via distribution partners in other geographies.  

· Installed base: A total of 106 Idylla(TM) instruments were added to the installed base in H1 2016, bringing the total to over 270 instruments as per 30 June 2016. A key driver behind the new installations was the expansion of the oncology menu by end 2015, which doubled from two to four tests with the launch of the Idylla(TM) NRAS-BRAF-EGFR S492R Mutation Assay and the Idylla(TM) ctBRAF Mutation Assay. Furthermore, the launch of the Idylla(TM) EGFR Mutation Assay on 21 June 2016 was another important element behind the installed base growth in H1 2016 as many clients had been waiting for this breakthrough test. Because of the launch timing of the Idylla(TM) EGFR Mutation Assay, a significant number of the new installations were placed with customers towards the end of Q2 2016.
· Cartridge consumption: Following installed base growth and the continued menu expansion, H1 2016 showed a significant pick-up in commercial cartridge consumption and associated product revenues. This demonstrates an initial validation of the 'razor-razorblade' approach that Biocartis follows. The total commercial cartridge volume in H1 2016 was equal to more than two times the volume for the full year 2015. The top selling product in H1 2016 was the Idylla(TM) KRAS Mutation Test (colorectal cancer), followed by the Idylla(TM) BRAF Mutation Test (melanoma cancer).

*Idylla(TM) test m* *enu highlights*
During H1 2016, Biocartis further advanced the development of new tests for its Idylla(TM) platform with a focus on completing its core menu for oncology (i.e. tests for melanoma, colon and lung cancer) and launching its second infectious disease test.

Oncology menu
Biocartis currently markets five oncology tests, consisting of four solid biopsy tests and one liquid biopsy test. To date, these tests generate most of the commercial cartridge revenues.

· Solid biopsy menu : On 21 June 2016, Biocartis realised another important milestone in completing its core menu for oncology with the launch of a test for lung cancer, the Idylla(TM) EGFR Mutation Assay (RUO ^[1] ). This advanced, fully automated molecular test is designed to detect over 50 EGFR mutations which commonly occur in lung cancer and demonstrates, amongst others, the high multiplex capabilities of the Idylla(TM) platform. A CE-IVD version of the Idylla(TM) EGFR Mutation Assay is planned for 2017. A liquid biopsy version is also under development. Furthermore, in H1 2016 Biocartis continued the additional validation work needed to obtain CE marking for its Idylla(TM) NRAS and NRAS/BRAF solid biopsy tests in H2 2016. Once obtained, Biocartis will be able to offer a complete RAS-BRAF analysis for clinical use on a same-day basis. The importance of offering this joint RAS-BRAF analysis was recently underlined with the new ESMO ^[2] guidelines as described below, which further opens up the route towards faster treatment selection ('same day results').
· Liquid biopsy menu: The promising results from liquid biopsies - which enable the identification of tumour mutations in the blood of patients - and concordance studies ^[3] currently being conducted are expected to further validate the clinical utility of these products. This underlines once more the importance of the various liquid biopsy tests Biocartis has under development. The development of liquid biopsy versions (RUO) of the Idylla(TM) KRAS Mutation Test and the Idylla(TM) NRAS-BRAF-EGFR S492R Mutation Assay, as part of the collaboration signed with Merck KGaA in January 2016, is on track for launch in H2 2016. Upon launch, Idylla(TM) is expected to be the only platform that can offer sample-to-result extended RAS testing, for both solid and liquid biopsies, on the same system.
· Performance of Idylla(TM) tests: In H1 2016, Biocartis' research partners published three papers and a study at ASCO ^[4] demonstrating the high quality of the Idylla(TM) tests on the market.

· Idylla(TM) ctBRAF Mutation Assay ^[5] : A publication by Dr. Filip Janku, PhD, assistant professor of Investigational Cancer Therapeutics at MD Anderson Cancer Center (Houston, US) and his team ^[6]  confirmed that the Idylla(TM) ctBRAF Mutation Assay can act as a faster and minimally invasive substitute for invasive tissue biopsy testing in advanced cancers such as melanoma or colorectal, which underlines that the test is perfectly suited for treatment monitoring. Similar findings were reported by Prof. Bart Neyns (Head of Medical Oncology, University Hospital Brussels, Belgium) and his team ^[7] .
· Idylla(TM) KRAS Mutation Test : A publication ^[8] by Prof. Troncone (University Federico II, Naples, Italy) researched the Idylla(TM) KRAS Mutation Test beyond the intended use of the test, in the setting of pancreatic cancer. The authors concluded ^8 that the Idylla(TM) platform could easily be implemented in routine assessment of pancreatic DNA samples to quickly provide information on KRAS mutational status.
· Idylla(TM) EGFR Mutation Assay ^5 : The new EGFR Mutation Assay was launched based on promising data from an alpha trial study which was accepted for publication at the upcoming ESMO meeting ^[9] . The study showed that the Idylla(TM) EGFR Mutation Assay demonstrated excellent specificity, sensitivity and ease of use combined with a fast turnaround time. Another study ^[10] by Prof. Troncone and colleagues (University Federico II, Naples, Italy) showed that >97% of lung cancer samples with insufficient DNA for Next Generation Sequencing (NGS) are still sufficient for testing with Idylla(TM). The study has been presented at the ASCO conference in June 2016.

· Market potential : Continued research shows that tumour mutation status (e.g. BRAF or KRAS) can drive several cancer types. Driven by such research, recently adopted ESMO guidelines ^[11] recommend that tumour BRAF mutation status should also be assessed alongside the tumour RAS mutational status in metastatic colorectal cancer (mCRC). Biocartis is uniquely positioned to respond to this new recommendation through its combined KRAS and NRAS-BRAF test offering in mCRC.

Infectious disease menu
Biocartis' focus within infectious diseases is on offering highly sensitive syndromic panel tests (initial focus on respiratory diseases), tests that support Biocartis' disease surveillance strategy and tests for fast monitoring of bloodstream infections ('BSI', including sepsis).

· Respiratory tests : Biocartis' partner Janssen Diagnostics successfully concluded US clinical studies for the Idylla(TM) Respiratory (IFV-RSV) Panel in H1 2016 to pursue US FDA 510k ^[12] clearance. The FDA submission file is currently being finalised, with expected submission in H2 2016.
· Disease surveillance: On 1 June 2016, Biocartis received Emergency Use Authorisation (EUA) by the U.S FDA for the Idylla(TM) Ebola Virus Triage Test that may be used to detect Ebola Zaire virus in patients with signs and symptoms of Ebola virus disease. Apart from being the first FDA achievement, this was a milestone for Biocartis as the Idylla(TM) Ebola Virus Triage Test is also a first cornerstone in its disease surveillance test offer. A collaborative study on the Idylla(TM) Ebola Virus Triage Test by the Institute of Tropical Medicine, Janssen Pharmaceutica, NIH (Bethesda, US) and Biocartis was published in the Journal of Infectious Diseases ^[13] , demonstrating that the Idylla(TM) test is fast, safe, easy to use and meets all performance criteria.

*Financial highlights*

· Product revenues: Total product revenues in H1 2016 grew 63% compared to H1 2015 from EUR 1.7m to EUR 2.7m. The increase in product revenues was driven by a strong growth in cartridge sales, which equalled EUR 1.7m in H1 2016 compared to EUR 0.4m in H1 2015 (increase of 314%). This was due to significantly higher commercial cartridge consumption and cartridges sold to Janssen Diagnostics for the US clinical studies of the Idylla(TM) Respiratory (IFV-RSV) Panel.
· System revenues: (i.e. Idylla(TM) Instrument and Idylla(TM) Console revenues) in H1 2016 amounted to EUR 1m compared to EUR 1.2m in H1 2015, representing a decrease of 21%. The cause of a decrease in system revenues is driven by an increased amount of commercial instruments that are placed with clients under different types of so-called operational lease contracts. These include a successful early adopter program which stimulates cartridge consumption at new customers, with the aim of securing long term commitments. Instrument revenues of operational lease contracts are recorded over the duration of the contract through lease payments made by customers.
· Total operating income: Total operating income in H1 2016 amounted to EUR 6.8m in H1 2016 compared to EUR 7.2m in H1 2015, representing a decrease of 7% due to increased product revenues that were offset by lower collaboration revenues. Collaboration revenues in H1 2016 included higher recognised upfront payments from strategic partners compared to H1 2015 (increase of 30%) but lower milestone payments (decrease of 100%) since one-off milestone payments of EUR 2m were received in H1 2015 whereas no milestone payments were collected in H1 2016.
· Financial debt: Post reporting date, on 20 July 2016 Biocartis announced that it has attracted EUR 55m of non-dilutive financing consisting of a EUR 40m bank and lease financing facility as well as a new subordinated loan of EUR 15m. The bank and lease financing facility consists of EUR 15m lease financing and EUR 25m multiple purpose credit lines (credit lines partially guaranteed by the Flemish Government through Gigarant). The lease financing will be used to finance the equipment of Biocartis' second cartridge manufacturing line and was signed before 30 June 2016. The other elements of the announced financing were signed in July 2016. As such, equipment investments for the second cartridge manufacturing facility made since initiation of the project in Q4 2015, were refinanced end of Q2 2016 with available lease financing. Following the above and including existing loans and lease facilities, total financial debt amounted to EUR 16.5m on 30 June 2016 compared to EUR 10.8m end of 2015.
· Net cash flow: Driven by increased operational expenses and higher investments for cartridge manufacturing expansion, of which most was refinanced with lease financing, the total net cash flow for H1 2016 amounted to EUR -28.3m.
· Cash position: Biocartis' cash position on 30 June 2016 amounted to EUR 75.8m compared to EUR 104.1m end of 2015 and approx. EUR 84m end of Q1 2016 (unaudited).

*Commenting on the H1 2016 results, Rudi Pauwels, Chief Executive Officer of Biocartis, said:* " The year 2016 for Biocartis is focused on translating our investments in installed base growth and menu expansion to exponentially increase the number of patients that can be helped by our solutions. I am pleased to see first evidence of this materialising in H1 2016. We managed to strengthen our financial position with a new non-dilutive financing of EUR 55m that we announced in July 2016. This financing will further support us in realising our ambitious growth trajectory that is aimed at making high quality molecular diagnostic solutions available -everywhere and every time healthcare workers and patients interact and need to make clinical and therapeutic decisions."

*Outlook 2016*

· Installed base: Following the H1 2016 performance, guidance for the installed base expansion is increased to the top end of the 150-175 range, bringing the forecasted total installed base to around 340 Idylla(TM) instruments by year end.
· Menu expansion: Guidance for launching at least four new tests in 2016 reiterated. The following test launches are expected in H2 2016:

· Liquid biopsy version of the Idylla(TM) KRAS Mutation Assay (RUO); and
· Liquid biopsy version of the Idylla(TM) NRAS-BRAF Mutation Assay (RUO).

· Regulatory events: The following regulatory events for existing Idylla(TM) tests are expected in H2 2016:

· CE-marking of Idylla(TM) NRAS Mutation Test and Idylla(TM) NRAS-BRAF Mutation Test solid biopsy tests;
· US FDA 510k submissions for the Idylla(TM) Respiratory (IFV-RSV) Panel and the Idylla(TM) Instrument and Idylla(TM) Console; and
· Continued product registration activities in other global markets, including South America, Latin America and Southeast Asia.

· Expected publication: Biocartis expects a publication by a renowned pharma company on an important study showing the key differences across a large number of KRAS Mutation detection technologies, incl. the Idylla(TM) KRAS Mutation Test, and their relevance in clinical practice, at the upcoming ESMO meeting in October 2016.
· Cash position: Guidance on target cash position by end 2016 in the range of EUR 45m to EUR 55m reiterated.

*Key figures for H1 2016*
The tables below show an overview of the key figures and a breakdown of operating income for H1 2016. Consolidated financial statements including notes are included in Biocartis' financial report for H1 2016 that can be downloaded from the Company's website here .

* Key figures (EUR 1,000) * *H1 2016* *H1 2015* *% Change*
*Total operating income* *6,750* *7,224* *-7%*
  Cost of sales -1,921 -1,158 66%
  Research & Development expenses -20,699 -16,092 29%
  Marketing & Distribution expenses -5,259 -3,219 63%
  General & Administrative expenses -2,874 -3,578 -20%
*Operating expenses* *-30,754* *-24,047* *28%*
*Operational result* *-24,003* *-16,823* *43%*
Net financial result -282 -429 -34%
Income tax 501 337 49%
*Net result* *-23,784* *-16,915* *41%*
Cash flow from operating activities -25,345 -8,719 191%
Cash flow from investing activities -6,912 -1,679 312%
Cash flow from financing activities 3,919 127,977 -97%
*Net cash flow* *-28,338* *117,579* *-124%*
*Cash and cash equivalents* ^1 *75,757* *128,477* *-41%*
Financial debt 16,544 10,815 53%

^1 Including EUR 1.2m of restricted cash (as a guarantee for KBC lease financing)

*Breakdown operating income (EUR 1,000)* *H1 2016* *H1 2015* *% Change*
*Collaboration revenue* *3,377* *4,866* *-31%*
  Idylla(TM) System Sales 988 1,246 -21%
  Cartridge Sales 1,723 416 314%
*Product sales revenue* *2,711* *1,663* *63%*
Service revenue 20 48 -58%
*Total revenue* *6,109* *6,577* *-7%*
Grants and other income 641 646 -1%
*Total operating income* *6,750* *7,224* *-7%*

Income statement
Collaboration revenues in H1 2016 showed an increase of recognised upfront payments that were received from strategic partners compared to H1 2015 (increase of 30%). No milestone payments were collected in H1 2016 compared to the EUR 2m of one-off milestone payments that were collected in H1 2015. This caused total collaboration revenues to decrease in H1 2016 to EUR 3.4m (EUR 4.9m in H1 2015). Product sales in H1 2016 increased with 63% compared to H1 2015 to EUR 2.7m. Grants and other income in H1 2016 consisted of various R&D project grants. Total operating income in H1 2016 amounted consequently to EUR 6.8m versus EUR 7.2m in H1 2015.

Total operating expenses in H1 2016 equalled EUR 30.8m compared to EUR 24.0m in H1 2015, an increase of 28% driven by higher expenses in R&D as well as in Marketing and Distribution. R&D expenses increased from EUR 16.1m in H1 2015 to EUR 20.7m in H1 2016 (increase of EUR 4.6m) as consequence of a growth of the R&D team to support continued menu and platform expansion as well as to support life cycle management for the increased number of on-market products. Marketing and distribution expenses increased from EUR 3.2m in H1 2015 to EUR 5.3m in H1 2016 (increase of EUR 2.0m) as consequence of an expansion of the sales team and higher sales and promotional expenses. G&A expenses decreased in H1 2016 to EUR 2.9m compared to EUR 3.6m in H1 2015, driven by one-off expenses for external advice in H1 2015 related to the Company's initial public offer (IPO) on Euronext Brussels. The above resulted in an operational result for H1 2016 equal to EUR -24.0m compared to EUR 16.8m in H1 2015 (decrease of EUR -7.2m). Following a net financial result for H1 2016 of EUR -0.3m and positive income taxes of EUR 0.5m, the net result for H1 2016 equalled to EUR -23.8m compared to EUR -16.9m for the same period in 2015.
Balance sheet
Property, plant and equipment increased in H1 2016 to EUR 17.0m from EUR 14.2m at the end of 2015 (increase of EUR 2.8m) driven by capital expenditure additions in H1 2016 of EUR 4.8m and a depreciation charge of around EUR 2.0m.

Inventory increased from EUR 5.8m per 31 December 2015 to EUR 9.0m per 30 June 2016 (increase of EUR 3.2m) driven by an overall higher instrumentation and cartridge inventory in light of expected increased commercialisation in H2 2016 and due to Idylla(TM) systems that are placed at customers under the Company's early adopter program. Trade receivables in H1 2016 decreased from EUR 5.9m end of 2015 to EUR 2.1m due to the collection of upfront and milestone payments from strategic partners recorded end of 2015. Trade payables end of H1 2016 amounted to EUR 6.7m which is a decrease of 7.3m compared to the EUR 13.9m as per 31 December 2015, mainly driven by the payment of advance invoices in relation to the second cartridge manufacturing line that were recorded end of 2015. Deferred income has decreased to EUR 3.6m per 30 June 2016, from EUR 5.2m per 31 December 2015, mainly because of recognised upfront payments from Janssen Pharmaceutica in relation to the strategic licensing, development and commercialisation collaborations.

Total financial debt increased from EUR 10.8m as of 31 December 2015, to EUR 16.5m per 30 June 2016 (an increase of EUR 5.7m) driven by the new lease and bank financings for the manufacturing expansion.
The cash position of the Group on 30 June 2016 amounted to EUR 75.8m compared to EUR 104.1m per 31 December 2015.

Cash flow statement
The cash flow from operating activities in H1 2016 amounted to EUR -25.3m compared to EUR -8.7m H1 2015. This increase is the result of higher operating expenses and investments in working capital for H1 2016 compared to significant positive movements in working capital for H1 2015. The cash flow from investing activities in H1 2016 amounted to EUR -6.9m compared to EUR -1.7m in H1 2015 principally driven by the increased capital expenditure for the cartridge manufacturing expansion. The cash flow from financing activities in H1 2016 amounted to EUR 3.9m, mainly driven by proceeds of the lease and bank financing for the cartridge manufacturing equipment. In H1 2015 the cash flow from financing activities amounted to EUR 128.0m thanks to the cash inflow from the IPO (EUR 107.0m) in April 2015 and the capital increase of the second tranche of the series F round (EUR 21.5m) in January 2015. The Group's net cash flow in H1 2016 amounted to EUR -28.3m.

*Financial calendar*

· Q3 Business Update 2016: 17 November 2016
· Full year results 2016: 2 March 2017

*Webcast and presentation*
The Biocartis management team will host a conference call with live webcast, during which the H1 2016 results will be presented, followed by a Q&A session. This event will be held today, 6 September 2016 at 14:00 CEST. The webcast can be accessed by clicking here . If you would like to participate in the Q&A, please dial +44(0)20 3427 1908 (standard international) with confirmation code 6014209. A replay of the webcast will be available on the Biocartis investors' website shortly after.

*Auditor Statement*
The condensed consolidated financial statements for the six month's period ended 30 June 2016 have been prepared in accordance with IAS 34 'Interim Financial Reporting' as adopted by the European Union. They do not include all the information required for the full annual financial statements and should therefore be read in conjunction with the financial statements for the year ended 31 December 2015. The condensed consolidated financial statements are presented in thousands of Euros (unless stated otherwise). The condensed consolidated financial statements have been approved for issue by the Board of Directors on 1 September 2016. The statutory auditor, Deloitte Bedrijfsrevisoren/Reviseurs d'Entreprises, represented by Gert Vanhees, has performed a limited review, which did not reveal any significant adjustments to the condensed consolidated financial statements. The interim financial report 2016 and the limited review opinion of the auditor are available on www.biocartis.com .

*--- END ---*

*More information:*
Renate Degrave
Manager Corporate Communications & Investor Relations
e-mail   rdegrave@biocartis.com
tel         +32 15 631 729
mobile   +32 471 53 60 64

*About Biocartis *
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla(TM) platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis has five oncology tests and two infectious disease tests on the market. More information:  www.biocartis.com . Press Photo Library available here . Follow us on Twitter : @Biocartis_.

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future.  In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. 
--------------------

^[1] Epidermal Growth Factor Receptor. The Idylla(TM) EGFR Mutation Assay is intended for Research Use Only (RUO), not for diagnostic procedures. Not for sale in the USA and Canada.

^[2] European Society for Medical Oncology. Source: E. Van Cutsem et al, 'ESMO consensus guidelines for the management of patients with metastatic colorectal cancer', Annals of Oncology, published July 5, 2016.

^[3] Diaz LA, Jr., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014; 32: 579-586; Siravegna G, Bardelli A. Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance. Genome Biol 2014; 15: 449; and Montagut C, Dalmases A, Bellosillo B et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med 2012; 18: 221-223.

^[4] American Society of Clinical Oncology.

^[5] Intended for Research Use Only, not for diagnostic procedures. Not for sale in the USA and Canada.

^[6] Janku et al. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Mol Cancer Ther (2016) 15(6): 1-8.

^[7] Schreuer et al. Quantitative assessment of BRAF V600 mutant cell-free tumor DNA from plasma as a diagnostic and therapeutic biomarker in patients with BRAF V600 mutant melanoma. ASCO 2015.

^[8] De Biase et al. 'Fully Automated PCR detection of KRAS Mutations on Pancreatic Endoscopic Ultrasound Fine Needle Aspirates'. J Clin Pathol 2016.

^[9] Reijans et al. ESMO 2016, to be published on 6 October 2016.

^[10] De Luca et al., J Clin Pathol 2016.

^[11] E. Van Cutsem et al, ESMO consensus guidelines for the management of patients with metastatic colorectal cancer, Annals of Oncology Advance Access published July 5, 2016.

^[12] 510k clearance is a requirement by the FDA before a product is allowed on the US market. It requires a number of technical or clinical studies.  

^[13] Cnops et al. Development, Evaluation, and Integration of a Quantitative Reverse-Transcription Polymerase Chain Reaction Diagnostic Test for Ebola Virus on a Molecular Diagnostics Platform. J Inf Dis 2016. doi: 10.1093/infdis/jiw150.

Financial Report H1 2016 Results Biocartis ENG FINAL
--------------------This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Biocartis Group NV via GlobeNewswire

HUG#2039772 Reported by GlobeNewswire 4 hours ago.
Viewing all 40166 articles
Browse latest View live




Latest Images